Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions

GLIA

Volumn 52, Issue 3, 2005, Pages 177-189

  Halstead, Susan K ^a   Morrison, Ian ^a   O'Hanlon, Graham M ^a   Humphreys, Peter D ^a   Goodfellow, John A ^a   Plomp, Jaap J ^b   Willison, Hugh J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoantibody; Ganglioside; Glia; Synapse

Indexed keywords

ALPHA LATROTOXIN; AUTOANTIBODY; DISIALOSYL ANTIBODY; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3; GANGLIOSIDE GQ 1B; GANGLIOSIDE GT 1A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; EVOKED RESPONSE; EXON; GLIA; HOMEOSTASIS; MALE; MOTOR NERVE; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NEUROPATHY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; SCHWANN CELL; SYNAPSE; SYNAPTIC MEMBRANE;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CELL MEMBRANE; EPITOPES; GANGLIOSIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; MOTOR NEURONS; N-ACETYLNEURAMINIC ACID; NERVE DEGENERATION; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR JUNCTION DISEASES; PRESYNAPTIC TERMINALS; SCHWANN CELLS;

EID: 30444447199     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20228     Document Type: Article

References (43)

1. Andersen SM, Ling CC, Zhang P, Townson K, Willison HJ, Bundle DR. 2004. Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome. Org Biomol Chem 2:1199-1212.
2. 2+-dependent vesicular exocytosis from synaptosomes. Biochimie 82:453-468.
3. Auld DS, Robitaille R. 2003a. Glial cells and neurotransmission: an inclusive view of synaptic function. Neuron 40:389-400.
4. Auld DS, Robitaille R. 2003b. Perisynaptic Schwann cells at the neuromuscular junction: nerve- and activity-dependent contributions to synaptic efficacy, plasticity, and reinnervation. Neuroscientist 9:144-157.
5. Boffey J, Nicholl D, Wagner ER, Townson K, Goodyear C, Furukawa K, Furukawa K, Conner J, Willison HJ. 2004. Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes. J Neuroimmunol 152:98-111.
6. Bullens RWM, O'Hanlon GM, Goodyear S, Molenaar P, Conner J, Willison HJ, Plomp JJ. 2000. Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates. Muscle Nerve 23:1035-1043.
7. Bullens RWM, O'Hanlon GM, Wagner E, Molenaar PC, Furukawa K, Plomp JJ, Willison HJ. 2002. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J Neurosci 22:6876-6884.
8. Castonguay A, Levesque S, Robitaille R. 2001. Glial cells as active partners in synaptic functions. Prog Brain Res 132:227-240.
9. Chapman PB, Yuasa H, Houghton AN. 1990. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol 145:891-898.
10. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. 1992. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31:677-679.
11. Colomar A, Robitaille R. 2004. Glial modulation of synaptic transmission at the neuromuscular junction. Glia 47:284-289.
12. Dippold WG, Lloyd KO, Li LT, Ikeda H, Oettgen HF, Old LJ. 1980. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA 77:6114-6118.
13. Duchen LW, Gomez S, Queiroz LS. 1981. The neuromuscular junction of the mouse after black widow spider venom. J Physiol (Lond) 316:279-291.
14. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RWM, Molenaar PC, Conner J, Willison HJ. 1999. Monoclonal antibodies raised against Guillain Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyse nerve muscle preparations. J Clin Invest 104:697-708.
15. Halstead SK, O'Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ, Plomp JJ, Willison HJ. 2004. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127:2109-2123.
16. Ho TW, Hsieh S-T, Nachamkin I, Willison HJ, Sheikh K, Kiehlbauch J, Flanigan K, McArthur JC, Cornblath DR, McKhann GM, Griffin JW. 1997. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 48:717-724.
17. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP. 2001. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98:442-449.
18. Jacobs BC, Bullens RW, O'Hanlon GM, Ang CW, Willison HJ, Plomp JJ. 2002. Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome. Muscle Nerve 25:549-558.
19. Koga M, Yoshino H, Morimatsu M, Yuki N. 2002. Anti-GT1a IgG in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 72:767-771.
20. Kremer DM, Lopez PHH, Mizutamari RK, Kremer LJ, Bacile EA, Nores GA. 1997. Factors defining target specificity in antibody-mediated neuropathy: density-dependent binding of anti-GD1a polyclonal IgG from a neurological patient. J Neurosci Res 47:636-641.
21. Lang B, Vincent A. 2003. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2:94-100.
22. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. 1995. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332:1467-1474.
23. Lloyd KO, Gordon CM, Thampoe IJ, DiBenedetto C. 1992. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res 52:4948-4953.
24. Marvaud JC, Raffestin S, Popoff MR. 2002. Botulism: the agent, mode of action of the botulinum neurotoxins, forms of acquisition, treatment and prevention. C R Biol 325:863-878.
25. McConville J, Vincent A. 2002. Diseases of the neuromuscular junction. Curr Opin Pharmacol 2:296-301.
26. O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison I, Wagner ER, Goodyear CS, Yin X, Trapp BD, Conner J, Molenaar PC, Stewart S, Rowan EG, Willison HJ. 2001. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124:893-906.
27. O'Hanlon GM, Bullens RW, Plomp JJ, Willison HJ. 2002. Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective. Neurochem Res 27:697-709.
28. O'Hanlon GM, Humphreys PD, Goldman RS, Halstead SK, Bullens RW, Plomp JJ, Ushkaryov Y, Willison HJ. 2003. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 126:1-13.
29. O'Leary CP, Veitch J, Durward WF, Thomas AM, Rees JH, Willison HJ. 1996. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 61:649-651.
30. Plomp JJ, Molenaar PC, O'Hanlon GM, Jacobs BC, Veitch J, Daha MR, van Doom PA, van der Meché FGA, Vincent A, Morgan BP, Willison HJ. 1999. Miller Fisher anti-GQ1b antibodies: a-latrotoxin-like effects on motor end plates. Ann Neurol 45:189-199.
31. Reddy LV, Koirala S, Sugiura Y, Herrera AA, Ko C-P. 2003. Glial cells maintain synaptic structure and function and promote development of the neuromuscular junction in vivo. Neuron 40:563-580.
32. Roberts M, Willison H, Vincent A, Newsom-Davis J. 1994. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 343:454-455.
33. Rochon D, Rousse I, Robitaille R. 2001. Synapse-glia interactions at the mammalian neuromuscular junction. J Neurosci 21:3819-3829.
34. Spaans F, Vredeveld JW, Morre HH, Jacobs BC, De Baets MH. 2003. Dysfunction at the motor end-plate and axon membrane in Guillain-Barre syndrome: a single-fiber EMG study. Muscle Nerve 27:426-434.
35. Susuki K, Yuki N, Hirata K. 2001. Fine specificity of anti-GQ1b IgG and clinical features. J Neurol Sci 185:5-9.
36. Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, Okada M, Fukumoto S, Haraguchi M, Takeda N, Fujimura K, Sakae M, Kishikawa M, Shiku H, Furukawa K, Aizawa S. 1996. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 93:10662-10667.
37. Tatewaki K, Yamaki T, Maeda Y, Tobioka H, Piao H, Yu H, Ibayashi Y, Sawada N, Hashi K. 1997. Cell density regulates crypticity of GM3 ganglioside on human glioma cells. Exp Cell Res 233:145-154.
38. Uncini A, Lugaresi A. 1999. Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. Muscle Nerve 22:640-644.
39. Willison HJ, O'Hanlon GM. 1999. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 100:3-12.
40. Willison HJ, O'Hanlon GM, Paterson G, Veitch J, Wilson G, Roberts M, Tang T, Vincent A. 1996. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J Clin Invest 97:1155-1164.
41. Willison HJ, Townson K, Veitch J, Boffey J, Isaacs N, Andersen SM, Zhang P, Ling CC, Bundle DR. 2004. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 127:680-691.
42. Willison HJ, Yuki N. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:1-35.
43. Wirguin I, Ifergane G, Almog Y, Lieberman D, Bersudsky M, Herishanu YO. 2002. Presynaptic neuromuscular transmission block in Guillain-Barre syndrome associated with anti-GQ1b antibodies. Neuromuscul Disord 12:292-293.